国寿股权公司姜黎：未来将重点布局AI、AI+和具身智能等领域

Group 1 - The company will continue to focus on investments in biomedicine, medical devices, and semiconductors, while also expanding into AI, AI+, and embodied intelligent robotics [1][2] - The company has established four funds with a total scale of 32 billion yuan, primarily focusing on mid-to-late stage investments, with a notable fund being the Guoshou Health Fund [2][3] - The investment amount in the semiconductor sector is increasing, surpassing that in biomedicine and medical devices, indicating a strategic shift towards hard technology and AI applications [2][3] Group 2 - The company is characterized as a long-term value investor, leveraging the resources of China Life, and aims to be a patient capital provider with investment horizons generally exceeding ten years [2][3] - The company is highly sensitive to risks and is actively exploring investment methods in emerging fields that are still in their early stages, despite facing certain challenges [2][3]